Barchart.com's Chart of the Day - iRadimed
Related Stocks
 IRMD - Iradimed Cp
SymLastChgPct
IRMD27.02-0.24-0.88%

The Barchart Chart of the Day belongs to the MRI products company iRadimed(IRMD). I found the stock by using Barchart to sort today's Top Stocks to Ownlist first by the highest Weighted Alpha, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 9/5 the stock gained 27.22%.

iRadimed Corporation engages in developing, manufacturing, marketing, and distributing magnetic resonance imaging (MRI) compatible products. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, IV poles, wireless remote displays/controls under the mRidium name; side car pump modules; dose error reduction systems; Masimo SET SpO2 monitoring products; and MRI Pulse oximeters, and MRI oximeter remotes and displays under the iMagox name used during MRI procedures. iRadimed Corporation is headquartered in Winter Park, Florida.

IRMD

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 261.20 Weighted Alpha
  • 248.44% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving average
  • 12 new highs and up 14.75% in the last month
  • Relative Strength Index 69.33%
  • Technical support level at 31.80
  • Recently traded at 33.45 with a 50 day moving average of 27.02

Fundamental factors:

  • Market Cap $337 million
  • P/E 120.77
  • Revenue expected to grow 31.00% this year and another 32.90% next year
  • Earnings estimated to increase 113.60% this year, an additional 4890% next year and continue to compound at an annual rate of 17.50% for the next 5 years
  • Wall Street analysts issued 1 buy and 1 hold on the stock